The clinical outcomes of chronic myeloid leukemia patients harboring alternatively spliced BCR-ABL variants

Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia

(2017) Takashi Ishida et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML)

(2015) Silvia Marcé et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: Study by the Nagasaki CML Study Group

(2013) Hidehiro Itonaga et al.   LEUKEMIA RESEARCH

The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

(2011) T. O'Hare et al.   BLOOD

Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia

(2011) Nóra Meggyesi et al.   MEDICAL ONCOLOGY

BCR-ABL Truncation due to Premature Translation Termination as a Mechanism of Resistance to Kinase Inhibitors

(2009) Wanlong Ma et al.   ACTA HAEMATOLOGICA

An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor Therapy

(2008) Jennifer Laudadio et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations

(2008) T.-S. Lee et al.   MOLECULAR CANCER THERAPEUTICS